Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.-Reference-Cited by-同舟云学术

Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:8002-8002
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Chari Ajai¹,Martinez-Lopez Joaquin²,Mateos Maria-Victoria³,Blade Joan⁴,Lonial Sagar⁵,Benboubker Lotfi⁶,Rocafiguera Albert Oriol⁷,Arnulf Bertrand⁸,San-Miguel Jesus⁹,Pineiro Luis¹⁰,Jakubowiak Andrzej J.¹¹,De Boer Carla¹²,Wang Jianping¹³,Schecter Jordan Mark¹³,Moreau Philippe¹⁴

Affiliation:

1. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY;

2. Hospital-12-de-Octubre, Madrid, Spain;

3. University Hospital of Salamanca/IBSAL, Salamanca, Spain;

4. Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain;

5. Winship Cancer Institute, Emory University, Atlanta, GA;

6. Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France;

7. Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;

8. Hôpital Saint Louis, Paris, France;

9. Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain;

10. Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX;

11. University of Chicago Medical Center, Chicago, IL;